Physician profile
Eric D Molnar
NPI 1164866729
$4,385.15
in general payments reported to CMS, 2019-2025
33 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $137 · 2021: $204 · 2022: $583 · 2023: $1,028 · 2024: $927 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $901.53 | 2021-2025 | |
| Pfizer INC. | $588.68 | 2019-2025 | |
| Amgen INC. | $358.99 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $326.28 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $305.27 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $256.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $201.96 | 2019-2023 | Dificid, Steglatro, Belsomra |
| Idorsia Pharmaceuticals US INC | $191.24 | 2023-2024 | Quviviq |
| Amarin Pharma, INC. | $170.86 | 2019-2022 | |
| Lilly USA, LLC | $148.04 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $143.03 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $100.00 | 2019-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.95 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $69.72 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $63.25 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $58.87 | 2022 | |
| Mylan Specialty L.P. | $39.97 | 2023-2024 | Yupelri |
| Medtronic, INC. | $35.96 | 2023 | Guardian Connect |
| Avanir Pharmaceuticals, INC. | $29.63 | 2019 | |
| Grifols USA, LLC | $28.86 | 2019 | |
| Glaxosmithkline, LLC. | $28.79 | 2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $28.33 | 2019-2022 | |
| Gilead Sciences, INC. | $27.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $26.97 | 2019 | |
| Genentech USA, INC. | $25.72 | 2019 | |
| Becton, Dickinson and Company | $24.69 | 2024 | Bd Max System, Bd Max Instrument |
| Boston Scientific Corporation | $22.73 | 2023 | Spectra Wavewriter |
| Nestle Healthcare Nutrition INC. | $16.51 | 2023 | |
| Astellas Pharma US INC | $14.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.68 | 2022 | |
| Redhill Biopharma INC. | $14.28 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.87 | 2019 | |
| Ibsa Pharma INC. | $13.21 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Molnar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.